Atara Biotherapeutics News and Activities

Atara Biotherapeutics is a company listed under the stock ticker ATRA (US).

View the org chart displaying its 20 main executives

Most searched biographies at Atara Biotherapeutics

• Cokey Nguyen, President and Chief Executive Officer
• William Heiden, Director
• Gregory Ciongoli, Chairman of the Board

Popular executive movements at Atara Biotherapeutics

• Kevin Sarney has joined the company as Interim Chief Financial Officer  (posted on June 29 2026).
• Yanina Grant-Huerta, Chief Accounting Officer, will leave the company on Jul. 17, 2026  (posted on June 29 2026).
• Carol Gallagher, Independent Lead Director, has left the company  (posted on June 15 2026).

Click here to view some more movements at Atara Biotherapeutics

Create your alert
to follow the executive moves at Atara Biotherapeutics.

Atara Biotherapeutics has 2,424 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).
• Opthea will change its company name to Ceryvyn Therapeutics on Jul 9, 2026. (posted on July 9 2026).
• Tissium has just announced a $60 Million fundraising (posted on July 8 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Atara Biotherapeutics

• News - Atara Biotherapeutics
• News - Atara Biotherapeutics
• Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 | Atara Biotherapeutics
• Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer | Atara Biotherapeutics
• Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference | Atara Biotherapeutics
• Login on Twitter
• Press Releases | Atara Biotherapeutics
• Facebook
• Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American
• Atara Biotherapeutics Announces Third Quarter 2018 Financial Results and Recent Operational Progress | Atara Biotherapeutics
• View more press releases Close

Social media about Atara Biotherapeutics

• Atara Biotherapeutics on Wikipedia, Google News & Yahoo Finance
• Atara Biotherapeutics on LinkedIn, X (Twitter) & YouTube